Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments
Clarivate (NYSE:CLVT) has announced the integration of Pathway Maps into its OFF-X translational safety intelligence solution. This enhancement aims to streamline safety evaluations in drug development, addressing the critical issue where over 30% of drug development failures are attributed to safety concerns.
The new Pathway Maps feature provides visual tools that combine disease-specific signaling pathways and molecular processes with curated safety data, enabling researchers to quickly identify potential safety liabilities. This integration helps research teams make faster, more informed decisions during the drug development process, from early discovery to post-marketing surveillance.
The enhanced OFF-X platform, when combined with Cortellis Drug Discovery Intelligence, offers researchers a comprehensive approach to evaluate both efficacy and safety in drug development, helping reduce costly late-stage failures and accelerate time to market.
Clarivate (NYSE:CLVT) ha annunciato l'integrazione di Pathway Maps nella sua soluzione di intelligence traslazionale sulla sicurezza OFF-X. Questo miglioramento mira a semplificare le valutazioni di sicurezza nello sviluppo dei farmaci, affrontando il problema critico per cui oltre il 30% dei fallimenti nello sviluppo farmaceutico è dovuto a questioni di sicurezza.
La nuova funzione Pathway Maps offre strumenti visivi che combinano percorsi di segnalazione specifici per malattia e processi molecolari con dati di sicurezza selezionati, permettendo ai ricercatori di individuare rapidamente potenziali rischi per la sicurezza. Questa integrazione supporta i team di ricerca nel prendere decisioni più rapide e informate durante tutto il processo di sviluppo del farmaco, dalla scoperta iniziale fino alla sorveglianza post-commercializzazione.
La piattaforma OFF-X potenziata, integrata con Cortellis Drug Discovery Intelligence, offre ai ricercatori un approccio completo per valutare sia l'efficacia che la sicurezza nello sviluppo dei farmaci, contribuendo a ridurre i costosi fallimenti nelle fasi avanzate e ad accelerare il time-to-market.
Clarivate (NYSE:CLVT) ha anunciado la integración de Pathway Maps en su solución de inteligencia traslacional de seguridad OFF-X. Esta mejora busca optimizar las evaluaciones de seguridad en el desarrollo de fármacos, abordando el problema crítico de que más del 30% de los fracasos en el desarrollo de medicamentos se deben a preocupaciones de seguridad.
La nueva función Pathway Maps ofrece herramientas visuales que combinan vías de señalización específicas de enfermedades y procesos moleculares con datos de seguridad seleccionados, permitiendo a los investigadores identificar rápidamente posibles riesgos de seguridad. Esta integración ayuda a los equipos de investigación a tomar decisiones más rápidas y fundamentadas durante el proceso de desarrollo del fármaco, desde el descubrimiento temprano hasta la vigilancia post-comercialización.
La plataforma mejorada OFF-X, combinada con Cortellis Drug Discovery Intelligence, ofrece a los investigadores un enfoque integral para evaluar tanto la eficacia como la seguridad en el desarrollo de medicamentos, ayudando a reducir fracasos costosos en etapas avanzadas y acelerar el tiempo de llegada al mercado.
Clarivate (NYSE:CLVT)가 자사의 OFF-X 전환 안전 인텔리전스 솔루션에 Pathway Maps를 통합했다고 발표했습니다. 이 기능 향상은 약물 개발 과정에서 안전성 평가를 간소화하는 것을 목표로 하며, 약물 개발 실패의 30% 이상이 안전 문제로 인한 것이라는 중요한 문제를 해결합니다.
새로운 Pathway Maps 기능은 질병별 신호 전달 경로와 분자 과정을 선별된 안전 데이터와 결합한 시각적 도구를 제공하여 연구자들이 잠재적 안전 위험을 빠르게 식별할 수 있도록 합니다. 이 통합은 연구팀이 초기 발견부터 시판 후 감시까지 약물 개발 과정에서 더 빠르고 정보에 기반한 결정을 내릴 수 있도록 돕습니다.
강화된 OFF-X 플랫폼은 Cortellis Drug Discovery Intelligence와 결합되어 연구자들에게 약물 개발에서 효능과 안전성을 모두 평가할 수 있는 포괄적인 접근법을 제공하며, 비용이 많이 드는 후기 단계 실패를 줄이고 시장 출시 시간을 단축하는 데 기여합니다.
Clarivate (NYSE:CLVT) a annoncé l’intégration de Pathway Maps dans sa solution d’intelligence translationnelle en sécurité OFF-X. Cette amélioration vise à simplifier les évaluations de sécurité dans le développement de médicaments, en répondant au problème crucial selon lequel plus de 30 % des échecs en développement pharmaceutique sont dus à des préoccupations de sécurité.
La nouvelle fonctionnalité Pathway Maps propose des outils visuels combinant les voies de signalisation spécifiques aux maladies et les processus moléculaires avec des données de sécurité sélectionnées, permettant aux chercheurs d’identifier rapidement les risques potentiels. Cette intégration aide les équipes de recherche à prendre des décisions plus rapides et mieux informées tout au long du processus de développement, de la découverte précoce à la surveillance post-commercialisation.
La plateforme OFF-X améliorée, associée à Cortellis Drug Discovery Intelligence, offre aux chercheurs une approche complète pour évaluer à la fois l’efficacité et la sécurité dans le développement des médicaments, contribuant à réduire les échecs coûteux en phase avancée et à accélérer la mise sur le marché.
Clarivate (NYSE:CLVT) hat die Integration von Pathway Maps in seine translationalen Sicherheits-Intelligence-Lösung OFF-X angekündigt. Diese Erweiterung zielt darauf ab, Sicherheitsbewertungen in der Arzneimittelentwicklung zu vereinfachen und adressiert das kritische Problem, dass über 30 % der Entwicklungsfehler von Medikamenten auf Sicherheitsbedenken zurückzuführen sind.
Die neue Pathway Maps-Funktion bietet visuelle Werkzeuge, die krankheitsspezifische Signalwege und molekulare Prozesse mit kuratierten Sicherheitsdaten kombinieren, sodass Forscher potenzielle Sicherheitsrisiken schnell identifizieren können. Diese Integration unterstützt Forschungsteams dabei, während des gesamten Entwicklungsprozesses von der frühen Entdeckung bis zur Marktnachbeobachtung schneller und fundierter Entscheidungen zu treffen.
Die verbesserte OFF-X-Plattform, kombiniert mit Cortellis Drug Discovery Intelligence, bietet Forschern einen umfassenden Ansatz zur Bewertung von Wirksamkeit und Sicherheit in der Arzneimittelentwicklung, hilft teure Fehlschläge in späten Phasen zu reduzieren und beschleunigt die Markteinführung.
- Integration of visual pathway maps with safety data streamlines target safety assessments
- Addresses 30% drug development failure rate due to safety issues
- Potential reduction in costly late-stage drug development failures
- Enhanced capability for early safety liability identification
- None.
R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights
Traditional safety data collection is often fragmented and time-consuming, creating delays in critical go/no-go decisions. With the addition of Pathway Maps to OFF-X, researchers can now explore disease-specific visualizations of key signaling pathways and molecular processes—uniquely overlaid with curated, multi-source safety data. This integration enables users to quickly pinpoint potential safety liabilities across upstream or downstream targets, adding biological context to risk assessment. By bringing together visual disease biology and comprehensive safety intelligence in one platform, OFF-X addresses a critical industry gap—empowering teams to make faster, more confident decisions across the drug development lifecycle.
Anne Lecocq, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, said: "The ability to assess the safety of drug targets early in development is a critical factor in reducing costly late-stage failures and accelerating time to market. At Clarivate, we're committed to empowering our customers with tools that not only streamline their workflows but also provide deeper, more actionable insights that improve patient lives and create a healthier tomorrow. The introduction of Pathway Maps into OFF-X is a game-changer—it integrates complex biological data with curated safety intelligence, helping researchers make confident, data-driven decisions faster and with greater accuracy."
With this release, OFF-X reaffirms its unique position as a platform that integrates proprietary physiological and disease pathway visualizations with curated safety data from diverse sources. This integration streamlines data access and enhances risk evaluation, providing researchers with the confidence to make more informed decisions and refine mitigation strategies.
Designed to support researchers throughout the drug development lifecycle—from early discovery to post-marketing surveillance— OFF-X offers a unified resource for translational safety intelligence. In the drug discovery and preclinical space, the combination OFF-X and Cortellis Drug Discovery Intelligence provides the most powerful approach for researchers to cover both efficacy and safety.
For more information on how OFF-X helps optimize target safety assessments, visit here.
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com
1 | Source: Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 2011;26(1):3-14. doi: 10.2133/dmpk.dmpk-10-rv-062. Epub October 22, 2010. PMID: 20978361; PMCID: PMC4707670. |
Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-enhances-off-x-with-pathway-maps-to-accelerate-target-safety-assessments-302453110.html
SOURCE Clarivate Plc
FAQ
What is the new feature added to Clarivate's OFF-X platform in May 2024?
How does Pathway Maps in OFF-X help drug development researchers?
What percentage of drug development failures are caused by safety issues according to Clarivate?
How does OFF-X integrate with Cortellis Drug Discovery Intelligence?
